Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2003
08/20/2003EP1335747A1 A composition of sodium channel blocking compound
08/20/2003EP1335739A2 Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof
08/20/2003EP1335738A2 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
08/20/2003EP1335730A1 Treatment of premature ejaculation
08/20/2003EP1335722A2 Compounds useful in the treatment of cns disorders
08/20/2003EP1335721A2 Method of treating and preventing migraine headaches
08/20/2003EP1335720A1 Sulphonamides for the treatment of central nervous system diseases
08/20/2003EP1335717A1 Treatment of pcp addiction and pcp addiction-related behavior
08/20/2003EP1335716A1 Novel use of combined 5-ht 1a agonists and selective serotonin reuptake inhibitors
08/20/2003EP1335646A2 Transgenic or recombinant non-human mammals and their uses in screening psycho-active medicines
08/20/2003EP1263504B1 Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina
08/20/2003EP1254139B1 4-heteroaryl-1,4-diazabicyclo 3.2.2]nonane, preparation and therapeutic use thereof
08/20/2003EP1212327B1 Pyrazolopyrimidines as therapeutic agents
08/20/2003EP1194415B1 Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for their preparation
08/20/2003EP1165566B1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
08/20/2003EP1165542B1 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
08/20/2003EP1135147B1 Method for producing medicaments from plant extracts, in a solid form of administration
08/20/2003EP1133297B1 Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
08/20/2003EP1086106B1 Furopyridine derivatives and their therapeutical use
08/20/2003EP1075489B1 Water-soluble prodrugs of 2,6-diisopropylphenol analogues
08/20/2003EP1067935B1 Acylbenzoxazines for enhancing synaptic response(s)
08/20/2003EP1053233B1 Hydroxamic and carboxylic acid derivatives
08/20/2003EP1047711B1 Nucleic acid sequences encoding capsaicin receptors
08/20/2003EP1017388B1 Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
08/20/2003EP0923542B1 Aryl substituted cyclic amines as selective dopamine d3 ligands
08/20/2003EP0900083B1 Novel substituted imidazole compounds
08/20/2003EP0877609B1 Formulation for intranasal administration
08/20/2003EP0804615B1 Apolipoprotein e polymorphism and treatment of alzheimer's disease
08/20/2003EP0799040B1 Trisubstituted thioxanthines
08/20/2003EP0697886B1 New peptide antagonists at glutamate and nmda receptors
08/20/2003CN1437608A O-aryl glucoside SGL T2 inhibitors and method
08/20/2003CN1437599A Tryasolyl tropane derivatives for therapy
08/20/2003CN1437598A Novel indole derivatives
08/20/2003CN1437597A Substituted phenyl-Piperazine derivatives, their preparation and use
08/20/2003CN1437596A Phenylpiperazinyl derivatives
08/20/2003CN1437595A Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals
08/20/2003CN1437591A Compounds and methods for modulation of estrogen receptors
08/20/2003CN1437588A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type l
08/20/2003CN1437584A Tricyclic protein kinase inhibitors
08/20/2003CN1437576A Substituted aminomethyl-phenyl-cyclohexane derivatives
08/20/2003CN1437575A Aminomethyl-phenyl-cyclohexanone derivatives
08/20/2003CN1437484A New formulation comprising a beta-blocker and optionally a cholesterol-lowering agent
08/20/2003CN1437477A A Memory enhancing protein
08/20/2003CN1437472A Highly concentrated stable meloxicam solutions
08/20/2003CN1437471A Benzothiazole derivatives
08/20/2003CN1437468A Halogentated 2-amino-5.6-heptenoic aicd derivatives useful as nitric oxide synthase inhibitors
08/20/2003CN1437463A System and method for treating a mucosal surface
08/20/2003CN1437462A Effervescence particles and preparing method thereof
08/20/2003CN1437442A Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological
08/20/2003CN1436782A Pyridine compounds and their prepn and application as Dopamine D4 receptor agonist
08/20/2003CN1436562A Hypericum perforatum extract and its prepn process and medicine composition
08/20/2003CN1436531A Donepezil hydrochloride dripping pills
08/20/2003CN1118468C Pyrazolopyrimidines and pyrazolotriazines
08/20/2003CN1118467C 1,3,8-triaza-spiro [4,5] decan-4-on derivatives
08/20/2003CN1118460C Pyrimidine derivatives as 5HT2C-receptor antagonists
08/20/2003CN1118454C Heterocyclic derivative and medicine
08/20/2003CN1118451C Acylated derivatives of melatonin and its analogues as medicine
08/20/2003CN1118308C Device for transfermal electrotransporting fentanyl and sufentanil
08/20/2003CN1118307C Device for transdermal electrotransport delivery of fentanyl and sufentanil
08/20/2003CN1118293C Medicine for quickly dropping drug
08/20/2003CN1118292C Medicine for quickly dropping drug
08/20/2003CN1118289C Health product for improving sleep
08/19/2003WO2003070947A1 Apoptosis promoter and inhibitor interacting with cgi-94 and method of screening the same
08/19/2003US6608197 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
08/19/2003US6608106 Contacting the cell with an amount of dehydroascorbic acid effective to increase the concentration of ascorbic acid in the cell
08/19/2003US6608105 For therapy and prophylaxis of diseases such as cachexia attributed to cancer or infections, rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus, rejection during bone marrow transplantation
08/19/2003US6608104 Gem substituted hydroxamic acids
08/19/2003US6608101 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
08/19/2003US6608088 Use of donerezil for the treatment of functional and/or organic pain syndromes
08/19/2003US6608087 Gyrase inhibitors and uses thereof
08/19/2003US6608085 Administering for neuroprotection
08/19/2003US6608083 Treatment and/or prophylaxis of convulsive disorders, renal disorders, urinary incontinence, ocular inflammation, eating disorders, inflammatory pain, allergic rhinitis, psoriasis,neurodegenerative disorders, Huntington's disease,
08/19/2003US6608080 Morphan derivatives or salts thereof and medicinal compositions containing the same
08/19/2003US6608079 Activating serotonin-1F receptors, inhibiting neuronal protein extravasation, treating migraine
08/19/2003US6608077 Il-8 receptor antagonists
08/19/2003US6608070 Useful for treatment of medical condition in which prostaglandins are implicated as pathogens
08/19/2003US6608064 Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas
08/19/2003US6608063 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
08/19/2003US6608062 Ligands for gamma-aminobutyric acid receptors; treatment and/or prevention of central nervous system disorders, including anxiety
08/19/2003US6608057 Compounds useful as reversible inhibitors of cathepsin S
08/19/2003US6608044 Inhibition of TNF activity
08/19/2003US6608035 Orally administering to mammal oligonucleotide of 15 to 30 nucleotides, comprising phosphorothioate linkages between nucleosides and 2'-O-alkoxyalkyl-ribonucleotides at each end, whereby oligonucleotide is intact in liver and kidney tissue
08/19/2003US6608031 Peptide comprising specified amino acid sequence
08/19/2003US6608030 Inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence
08/19/2003US6608029 Reducing gastric motility or delaying gastric emptying in mammal by administering therapeutically effective amount of amylin or amylin agonist, such as pramlintide or pramlintide acetate
08/19/2003US6607882 Regulation of endogenous gene expression in cells using zinc finger proteins
08/19/2003US6607758 Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses
08/19/2003US6607757 At least 13% glucoside isoflavones and 0.6-1.5 parts 3 soya saponins per 1 part by weight of glucoside isoflavones; treating pre or post menopausal symptoms, breast and prostate cancer, and alcoholism
08/19/2003CA2433180A1 Apoptosis promoting and suppressing substances interacting with cgi-94, and methods for screening the same
08/19/2003CA2079376C (bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
08/19/2003CA2067404C Benzoisothiazole and benzoisoxazole-3-carboxamides a process for their preparation and their use as medicaments
08/14/2003WO2003067221A2 Compositions and methods for restoring immune responsiveness in patients with immunological defects
08/14/2003WO2003066889A2 Assay for acytyltransferase or deacetylase activity
08/14/2003WO2003066881A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/14/2003WO2003066859A2 Amino acid sequences capable of facilitating penetration across a biological barrier
08/14/2003WO2003066840A2 Pluripotent embryonic-like stem cells derived from teeth and uses thereof
08/14/2003WO2003066822A2 Truncated aggrecanase molecules
08/14/2003WO2003066810A2 Recombinant bovine immunodeficiency virus based gene transfer system
08/14/2003WO2003066806A2 Therapeutic use of aziridino compounds
08/14/2003WO2003066672A1 Peptides
1 ... 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 ... 1833